



1c860 U.S. PTO
03/07/02

Please type a plus sign (+) inside this box 

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket	PTZ17C1
(Only for new nonprovisional applications under 37 CFR 1.53(b))		First Inventor	Rosen et al.
		Title	Nucleic Acids, Proteins, and Antibodies
		Express Mail Label	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		Box Patent Application ADDRESS TO: Commissioner for Patents Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)		7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)	
2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
3. <input checked="" type="checkbox"/> Specification [Total Pages 521] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure		a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)	
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets]		b. Specification Sequence Listing on: i. <input checked="" type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper	
5. Oath or Declaration [Total Pages 5] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)		c. <input checked="" type="checkbox"/> Statements verifying identity of above copies	
6. <input checked="" type="checkbox"/> Application Data Sheet See 37 CFR 1.76 (7 pages)		ACCOMPANYING APPLICATIONS PARTS	
		9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
		10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Associate Power of (when there is an assignee) Attorney	
		11. <input type="checkbox"/> English Translation Document (if applicable)	
		12. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations	
		13. <input type="checkbox"/> Preliminary Amendment	
		14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
		15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
		16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent	
		17. <input checked="" type="checkbox"/> Other 1. Statement Under 37 C.F.R. § 1.821 2. Transmittal and Submission Under 37 C.F.R. §§ 1.824 and 1.52(e)	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76 <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No. 09/764,879 Prior application information: Examiner Clow, L. Group / Art Unit: 1631 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.			
19. CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		22195 or <input type="checkbox"/> Correspondence address below	
Name			
Address			
City		State	Zip Code
Country		Telephone	Fax
Name (Print/Type)		Mark J. Hyman	Registration No (Attorney/Agent)
Signature			46,789
		Date	March 7, 2002

10094438-030702

10997 U.S. PTO
10/091438
03/07/02

<p>Under the Paperwork Reduction Act of 1993, no persons are required to supply this information unless it is requested by a person in an official capacity.</p>		<p>Complete if Known</p>	
<p>FEE TRANSMITTAL for FY 2002</p> <p><i>Patent fees are subject to annual revision.</i></p>		Application Number	Not Yet Assigned
		Filing Date	Herewith
		First Named Inventor	Rosen et al.
		Examiner Name	Not Yet Assigned
		Group Art Unit	Not Yet Assigned
		Attorney Docket No.	PTZ17C1
<p><input type="checkbox"/> Application claims small entity status. See 37 CFR 1.27</p>			
<p>TOTAL AMOUNT OF PAYMENT</p>		<p>(\$) 896.00</p>	

Patent fees are subject to annual revision.

☐ Application claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT	(\$)	896.00
--------------------------------	-------------	---------------

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Rosen et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	PTZ17C1

<input type="checkbox"/>	Check	<input type="checkbox"/>	Credit Card	<input type="checkbox"/>	Money Order	<input type="checkbox"/>	Other	<input type="checkbox"/>	None
--------------------------	-------	--------------------------	-------------	--------------------------	-------------	--------------------------	-------	--------------------------	------

☒ Deposit Account

Deposit
Account
Number

08-3425

Human Genome Sciences, Inc.

Name

The Commissioner is hereby authorized to: *(check all that apply)*

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

1. BASIC FILING FEE

	Large Entity	Small Entity
1. Revenue Recognition	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.
2. Expense Recognition	Expenses are recognized when the related asset is consumed or the liability is incurred.	Expenses are recognized when the related asset is consumed or the liability is incurred.
3. Asset Recognition	Assets are recognized when the company has control over a resource that is expected to generate future economic benefits.	Assets are recognized when the company has control over a resource that is expected to generate future economic benefits.
4. Liability Recognition	Liabilities are recognized when the company has a present obligation to transfer an asset or provide a service in the future.	Liabilities are recognized when the company has a present obligation to transfer an asset or provide a service in the future.
5. Equity Recognition	Equity is recognized as the residual interest in the assets of the company after deducting all liabilities.	Equity is recognized as the residual interest in the assets of the company after deducting all liabilities.

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	740.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1)	(S)	740.00
--------------	-----	--------

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	
Fee to	Fee from
1. Fee to	2. Fee from

2. EXTRA CLAIM FEE		Extra Claims	Fee from below	Fee Paid
Total Claims	24	-20** = 4	x 18.00	= 72.00
Independent Claims	4	-3** = 1	x 84.00	= 84.00
Multiple Dependent				

	Large Entity	Small Entity
1. Revenue Recognition	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.	Revenue is recognized when the performance obligation is satisfied, which is when control of the goods or services is transferred to the customer.
2. Expense Recognition	Expenses are recognized when the related asset is consumed or the liability is incurred.	Expenses are recognized when the related asset is consumed or the liability is incurred.
3. Asset Recognition	Assets are recognized when the company has control over the resource and it is probable that the resource will generate future economic benefits.	Assets are recognized when the company has control over the resource and it is probable that the resource will generate future economic benefits.
4. Liability Recognition	Liabilities are recognized when the company has a present obligation to transfer economic resources in the future.	Liabilities are recognized when the company has a present obligation to transfer economic resources in the future.
5. Equity Recognition	Equity is recognized as the residual interest in the assets of the company after deducting liabilities.	Equity is recognized as the residual interest in the assets of the company after deducting liabilities.

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)	(\$)	156.00
--------------	------	--------

** or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity
<p>1. Revenue Recognition</p> <p>Large entities use the percentage-of-completion method, which recognizes revenue and profit as the contract progresses. This method requires estimating the total contract revenue and the proportion of work completed.</p> <p>Small entities use the cost-of-sales method, which recognizes revenue only when the contract is completed. This method is simpler and less subjective.</p>	<p>1. Revenue Recognition</p> <p>Small entities use the cost-of-sales method, which recognizes revenue only when the contract is completed. This method is simpler and less subjective.</p>
<p>2. Asset Valuation</p> <p>Large entities use the lower of cost or market rule, which requires valuing inventory at the lower of its historical cost or its current market value. This rule is more complex and requires frequent market valuations.</p> <p>Small entities use the cost method, which values inventory at its historical cost. This method is simpler and less subjective.</p>	<p>2. Asset Valuation</p> <p>Small entities use the cost method, which values inventory at its historical cost. This method is simpler and less subjective.</p>
<p>3. Liability Recognition</p> <p>Large entities use the accrual method, which recognizes liabilities when they are incurred, regardless of when they are paid. This method is more complex and requires more judgment.</p> <p>Small entities use the cash method, which recognizes liabilities only when they are paid. This method is simpler and less subjective.</p>	<p>3. Liability Recognition</p> <p>Small entities use the cash method, which recognizes liabilities only when they are paid. This method is simpler and less subjective.</p>

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge – late filing fee or oath	
127	50	227	25	Surcharge – late provisional filing fee or cover sheet.	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive – unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid	SUBTOTAL (3)	(\$)	0.00
-----------------------------------	--------------	------	------

SUBMITTED BY

Name (Print/Type)	Mark J. Hyman
-------------------	---------------

Registration No.
(Attorney/Agent)

46.789

Complete (if applicable)

Telephone	(240) 314-1224
-----------	----------------

Date	March 7, 2002
------	---------------

VIA HAND DELIVERY MARCH 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PTZ17C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

STATEMENT UNDER 37 C.F.R. § 1.821


Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on compact disc) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: March 7, 2002



Mark J. Hyman
Attorney for Applicants

Reg. No. 46,789

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures

20020307 09:44:00

VIA HAND DELIVERY MARCH 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al. Attorney Docket No.: PTZ17C1
Application Serial No.: Not Yet Assigned Art Unit: Not Yet Assigned
Filed: Herewith Examiner: Not Yet Assigned
Title: Nucleic Acids, Proteins, and Antibodies

**TRANSMITTAL AND SUBMISSION UNDER
37 C.F.R. §§ 1.824 AND 1.52(e)**

Commissioner for Patents
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer readable format requirements on a compact disc (CD-R) labeled "CRF." Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-R). Applicants certify under 37 C.F.R. § 1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, each contain the file "PTZ17C1_seqList.txt" (788,255 bytes in size, created March 6, 2002).

Respectfully submitted,

Dated: March 7, 2002


Mark J. Hyman
Attorney for Applicants

Reg. No. 46,789

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures

SCANNED, # 12